Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes.
Age Factors
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Head and Neck Neoplasms
/ drug therapy
Humans
Neoplasm Metastasis
Randomized Controlled Trials as Topic
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
pubmed:
31
3
2021
medline:
25
8
2021
entrez:
30
3
2021
Statut:
ppublish
Résumé
Worldwide, head and neck carcinomas account for 5% of all malignancies. Two-thirds of patients relapse after initial multimodal therapy. Until early 2010, the median overall survival (OS) of metastatic patients was about 10 months. New drugs have been incorporated in patient management, thus enabling an increase in OS. Several first and second line protocols are now available but the lack of direct comparison makes the choice difficult between them. This work aims to define the comprehensive medical management of patients with relapsing head and neck carcinoma. In September 2020, the French head and neck groups GORTEC, Unicancer head and Neck group, GROCC and GETTEC decided to promote a one-day meeting to propose how to incorporate these new regimens in first and second line treatment for recurrent and metastatic head and neck cancer (R/M SCCHNC). Twelve French medical oncologist involved in the management of R/M SCCHNC for more than 10 years examined the literature and proposed a simple and practical management based on five criteria: age, delay from last platinum injection, combined positive score expression level, FIT or UNFIT patient according to physician decision, fast response needed or not.
Identifiants
pubmed: 33782359
doi: 10.1097/CCO.0000000000000738
pii: 00001622-202105000-00003
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
160-167Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 2010; 127:2893–2917.
Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993; 328:184–194.
Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257–263.
Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245–1251.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116–1127.
Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394:1915–1928.
Guigay J, Fayette J, Dillies AF, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol 2015; 26:1941–1947.
Guigay J, Even C, Mayache-Badis L, et al. Long-term response in patients with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPX) as first-line treatment followed by cetuximab maintenance. Oral Oncol 2017; 68:114–118.
Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021. doi: 10.1016/S1470-2045(20)30755-5. [Online ahead of print]
Cohen EEW, Soulières D, Le Tourneau C, et al. KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019; 393:156–167.
Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 2017; 18:1104–1115.
Gillison ML, Blumenschein G Jr, Fayette J, et al. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 2018; 23:1079–1082.
European medicines agency. Assessment report EMA/CHMP/591139/2019. available on line. https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c3820-ii-0065-epar-assessment-report-variation_en.pdf . Accessed on january 19, 2020.
Szturz P, Vermorken JB. Further clinical interpretation and implications of KEYNOTE-048 findings. Lancet 2020; 396:379PMID: 32771103.
Carinato H, Burgy M, Fischbach C, et al. Weekly paclitaxel, carboplatin and cetuximab (PCC)as first line treatment of reccurent and/or metastatic head and neck squamous cell carcinoma for patients ineligible to cisplatine based chemotherapy. Ann Oncol 2020; 31: (suppl_4): S599–S628.